Search fresh public links, source activity, and post angles for Db-Oto Gene Therapy.
Fresh curated links around DB-OTO gene therapy are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
If approved, Regeneron's Otarmeni will be the first gene therapy for OTOF-related hearing loss in the European Union.
The adeno-associated virus vector-based gene therapy is indicated for pediatric and adult patients with severe-to-profound hearing loss due to biallelic OTOF gene variants.
Otarmeni, now cleared to treat a rare, inherited kind of hearing loss, is the first gene therapy cleared under the FDA’s “national priority” voucher program and will be offered to...
A multicenter study found a one-time treatment targeting the OTOF gene restored hearing in most participants, with effects lasting up to 2.5 years.
THURSDAY, April 23, 2026 — A new gene therapy to treat inherited deafness produces a lasting cure, a new international study has found. The treatment, which targets the OTOF gene,...
MONDAY, April 27, 2026 — In a historic leap for medical science, the U.S. Food and Drug Administration (FDA) has greenlit the first-ever gene therapy to treat a rare form of inheri...
Regeneron Pharmaceuticals’ Otarmeni is now approved for treating hearing loss from an ultra-rare genetic mutation found in an estimated 50 newborns per year. While Regeneron will o...
Washington, United States: US health officials on Thursday greenlit a first-of-its-kind gene therapy to treat a rare form of hereditary hearing loss, a breakthrough which could pa...
The treatment, developed by Regeneron Pharmaceuticals, is for a very rare form of deafness. But it represents a medical milestone.
Critical Path Institute Awards $249,719 Grant to Odylia Therapeutics for Groundbreaking Gene Therapy Targeting Usher Syndrome Type 1C Vision Loss In an ambitious effort to combat a...
Researchers say a gene therapy allowed deaf children and adults as old as 32 to hear for the first time. The benefits have persisted for more than two years for some patients.
US health officials on Thursday greenlit a first-of-its-kind gene therapy to treat a rare form of hereditary hearing loss, a breakthrough that could pave the way for other such hea...
The treatment, the first of its kind, was approved by the Food and Drug Administration on Thursday. “Our baby was born deaf, and now he can hear,” said one parent.
The therapy is part of a plan to develop gene therapies that can be efficiently delivered at lower doses, enabling them to be used against more than just “ultra-rare” conditions.
Travis Smith was 1 year old when he underwent surgery on both ears. He's now babbling, dancing and laughing.
La agencia reguladora estadounidense autorizó un fármaco que utiliza vectores virales para restaurar la proteína otoferlina en niños, permitiendo que el cerebro procese el sonido d...
Travis Smith was a very serious baby. Born completely unable to hear, his mother, Sierra, struggled to see his personality shine through his mute world.
Though two serious side effects muddied the results, CEO Curran Simpson expressed optimism about a clearance and claimed FDA leadership will have a “mandate on rare disease flexibi...
Many gene therapy outfits focus on technical advances, Ocugen CEO Shankar Musunuri, Ph.D., said, meaning they miss out on broader commercial success.
In a groundbreaking study published in Cell Death Discovery, researchers led by Chien, JY., Woon, P.Y., and Tsai, HY. have illuminated a previously uncharted pathway in retinal deg...
A breakthrough FDA-approved treatment is changing how genetic deafness is treated.
I’ve been trying to dig out from all the stuff that piled up while I was working toward a big grant deadline last week, catch up on recent news and papers, and during this time I w...
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.